Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Just the facts …need to be understood
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(892)
•••
Comment by westcoast1000on Dec 30, 2022 4:53pm
248 Views
Post# 35197771

RE:RE:RE:RE:RE:Just the facts …need to be understood

RE:RE:RE:RE:RE:Just the facts …need to be understood Thanks to Prob for an excellent post.

We need to be reminded of these points over and over because of the negative sentiment as shown by the share price, and of course the steady (or even worse, the subtle, intermittent) comments from an array of bashers.

Clearly the results of the last year mean the company has substantial value as a potential big pharma aquisition.

The comment that the board did oust Brad (probably for complete lack of planning) is am important reminder. Also the addition of the two board members that were recently appointed to pursue a sale is an important indication.

They each got 45 k in options. Those two former CEOs will want to get value out of those options sooner rather than later.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities